New Antibiotics in Pulmonary and Critical Care Medicine

†, * University of the Pacific, School of Pharmacy Stockton, California, and Kendle International, Inc.;   †Maine Medical Center, Portland, Maine, and University of Vermont, College of Medicine, Burlington, Vermont

Semin Respir Crit Care Med. 2000;21(1) 

In This Article


Many new antibiotics have been made available for use over the last year, most of which are indicated for the treatment of either community- or hospital- acquired pulmonary infections. The introduction of such agents comes at a time when resistant pathogens are becoming an emerging threat to patient survival. The emergence of bacterial resistance in our most severely ill patient populations has extensive implications associated with mortality, morbidity, and cost of care. Broad sweeping surveillance studies are useful to detect regional susceptibility changes; however, the most important data to the practicing clinician must be obtained locally to determine pathogens that must be addressed on an institutional level. Improved diagnostic testing may assist the clinician in the determination of an etiologic agent or in confirming the presence or absence of infection. Newer antibiotic therapies may save patients or stave off resistance, temporarily. From a larger perspective, however, nothing may have a greater impact on the prevention of resistance and ultimately increase survival, than the judicious use of existing therapies and employing sound clinical judgment in the antibiotic selection process as well as in the design of optimal dosing regimens.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.